This Study is a Non-Randomized, Open-Label, Multi-Center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2008 Positive results reported at ESMO according to GlaxoSmithKline media release.